← Leaderboards
Carlos S Subauste
University Of Cincinnati
$14,076,625
Attributed
$14,076,625
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,076,625 · 8
By mechanism
R01$11,053,556 · 4
P30$3,023,069 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Cincinnati
Same institution · by research overlap
- June Goto$615,442
- S Kevin Li$7,494,887
- Yoonjee Park$1,075,600
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoPreventLeadResistanceSignal TransductionMediatingProteinsRetinaEndothelial CellsBlindnessTransgenic MiceTnfrsf5 GeneCytokineBaseRetinalResearch PersonnelResponseProductionGeneticEventProtein KinasePathway InteractionsTissues
Grant awards (46)
Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease$354,200
R01 · FY2025 · DK · contact PI
Analytical Services Core$329,380
P30 · FY2025 · EY · contact PI
Autophagy and Ocular Toxoplasmosis$365,378
R01 · FY2024 · EY · contact PI
Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease$329,725
R01 · FY2024 · DK · contact PI
Analytical Services Core$329,380
P30 · FY2024 · EY · contact PI
Autophagy and Ocular Toxoplasmosis$379,224
R01 · FY2023 · EY · contact PI
Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease$354,200
R01 · FY2023 · DK · contact PI
Analytical Services Core$329,380
P30 · FY2023 · EY · contact PI
Regulation of retinopathies$390,425
R01 · FY2022 · EY · contact PI
Autophagy and Ocular Toxoplasmosis$376,519
R01 · FY2022 · EY · contact PI
Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease$354,200
R01 · FY2022 · DK · contact PI
Analytical Services Core$329,380
P30 · FY2022 · EY · contact PI
Regulation of retinopathies$390,425
R01 · FY2021 · EY · contact PI
Autophagy and Ocular Toxoplasmosis$382,389
R01 · FY2021 · EY · contact PI
Histology, Microscopy, and Imaging Core$178,574
P30 · FY2021 · EY · contact PI
Regulation of retinopathies$401,875
R01 · FY2020 · EY · contact PI
Autophagy and Ocular Toxoplasmosis$385,880
R01 · FY2020 · EY · contact PI
Histology, Microscopy, and Imaging Core$178,574
P30 · FY2020 · EY · contact PI
Regulation of retinopathies$400,000
R01 · FY2019 · EY · contact PI
Histology, Microscopy, and Imaging Core$177,649
P30 · FY2019 · EY · contact PI
Regulation of retinopathies$400,000
R01 · FY2018 · EY · contact PI
Histology, Microscopy, and Imaging Core$177,465
P30 · FY2018 · EY · contact PI
Autophagy and ocular toxoplasmosis.$419,575
R01 · FY2017 · EY · contact PI
Histology, Microscopy, and Imaging Core$177,465
P30 · FY2017 · EY · contact PI
Autophagy and ocular toxoplasmosis.$356,625
R01 · FY2016 · EY · contact PI
Tissue Culture and Hybridoma$163,165
P30 · FY2016 · EY · contact PI
Autophagy and ocular toxoplasmosis.$62,950
R01 · FY2016 · EY · contact PI
Autophagy and ocular toxoplasmosis.$356,625
R01 · FY2015 · EY · contact PI
Tissue Culture and Hybridoma$163,165
P30 · FY2015 · EY · contact PI
Regulation of retinopathies$332,338
R01 · FY2014 · EY · contact PI
Tissue Culture and Hybridoma$163,164
P30 · FY2014 · EY · contact PI
Autophagy and ocular toxoplasmosis$354,380
R01 · FY2013 · EY · contact PI
Regulation of retinopathies$322,164
R01 · FY2013 · EY · contact PI
Tissue Culture and Hybridoma$163,164
P30 · FY2013 · EY · contact PI
Autophagy and ocular toxoplasmosis$373,032
R01 · FY2012 · EY · contact PI
Regulation of retinopathies$339,120
R01 · FY2012 · EY · contact PI
Tissue Culture and Hybridoma$163,164
P30 · FY2012 · EY · contact PI
Autophagy and ocular toxoplasmosis$373,032
R01 · FY2011 · EY · contact PI
Regulation of retinopathies$339,120
R01 · FY2011 · EY · contact PI
Autophagy and ocular toxoplasmosis$388,575
R01 · FY2010 · EY · contact PI
Regulation of retinopathies$353,250
R01 · FY2010 · EY · contact PI
Autophagy and ocular toxoplasmosis$392,500
R01 · FY2009 · EY · contact PI
CD40 Ligand: Therapy for Opportunistic Pathogens and HIV$267,750
R01 · FY2004 · AI
CD40 Ligand: Therapy for Opportunistic Pathogens and HIV$267,750
R01 · FY2003 · AI
CD40 Ligand: Therapy for Opportunistic Pathogens and HIV$254,363
R01 · FY2002 · AI
CD40 Ligand: Therapy for Opportunistic Pathogens and HIV$235,967
R01 · FY2001 · AI